证券代码：002675 证券简称：东诚药业 公告编号：2025-027 烟台东诚药业集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 2.本次股东大会未涉及变更前次股东大会决议。 一、会议召开情况 （一）召开时间： 现场会议时间：2025年5月15日（星期四）14:50； 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025年5月15日9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2025年5月15日9:15-15:00期间的任意时间。 （二）现场会议地点：烟台经济技术开发区长白山路7号公司会议室； （六）本次股东大会的召集、召开程序符合《公司法》《上市公司股东大会 规则》等法律、法规、规范性文件和《公司章程》的规定。 二、会议出席情况 参加本次会议的股东及股东代理人共137人，代表公司有表决权的股份 357,008,886股，占公司有表决权股份总数的43.2950%。其中：1、出席本次现场 会议的股东及股东代 ...

北京市中伦律师事务所 关于烟台东诚药业集团股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：烟台东诚药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和 国证券法》及中国证券监督管理委员会发布的《上市公司股东会规则》等规定， 北京市中伦律师事务所（以下简称本所）接受烟台东诚药业集团股份有限公司（以 下简称公司）的委托，指派本所律师对公司 2025 年第一次临时股东大会（以下 简称本次股东大会）进行见证并就相关事项出具本法律意见书。 为出具本法律意见书，本所律师查阅了公司提供的相关文件，包括但不限于： 1. 现行《烟台东诚药业集团股份有限公司章程》（以下简称《公司章程》）； 2. 公司于 2025 年 4 月 30 日刊登在深圳证券交易所网站（www.szse.cn）、 巨潮资讯网（www.cninfo.com.cn）的第六届董事会第十次会议决议公告、关于召 开本次股东大会的通知； 3. 公司本次股东大会股权登记日（2025 年 5 月 9 日）的股东名册、出席现 场会议的股东的到会登记记录及凭证资料； 4. 公司本次股东大会的会议文件。 1 法律意见书 在本法 ...

Summary of Key Points from the Conference Call of Jianyou Co., Ltd. Company Overview - Jianyou Co., Ltd. started with heparin raw materials and has gradually developed into enoxaparin sodium injections, small molecule injections, and large molecule biosimilars, establishing three growth curves with significant synergy in the industrial chain, production technology, registration, commercialization, and marketing [2][4] Core Business and Market Position - The company has a strong presence in the U.S. market, with formulation revenue accounting for over 70% and overseas formulation revenue approximately 54% [2][9] - The heparin preparation market has a natural growth rate of about 5%, with a projected global market size of $6.05 billion in 2024, expected to reach around $10 billion by 2034 [5][25] - The biosimilar market is expected to grow significantly, with projections of a market size between $30 billion and $35.5 billion in 2024, potentially reaching over $120 billion by 2032 [11][12] Future Growth Drivers - The U.S. Inflation Reduction Act (IRA) is expected to enhance the profitability of biosimilars by restructuring insurance payment systems, encouraging doctors to prescribe lower-cost biosimilars [2][13] - Jianyou's biosimilar products, such as adalimumab, are anticipated to generate $30 million in sales by 2025, with significant orders for liraglutide and plans for rapid approval of high-concentration adalimumab [2][14][16] Production and Capacity - The company has 12 FDA-approved injection production lines, with capacity utilization expected to reach 80%-90% by the end of 2026 to 2027 [2][21] - The U.S. sterile injection market is in a long-term shortage, providing Jianyou with a competitive advantage due to its strong commercialization capabilities and production capacity [2][21] Financial Performance and Projections - Expected revenues for 2025 and 2026 are projected to be $5.5 billion and $7 billion, respectively, with net profits ranging from $1.15 billion to $1.5 billion [5][29] - The overall revenue growth rate is expected to reach 30%-34.8%, driven by high-margin products and a stable domestic market [29] Strategic Advantages - Jianyou has significant advantages in the industrial chain, including vertical integration from raw materials to finished products, ensuring product quality and pricing power [6] - The company has developed strong sales networks through acquisitions and partnerships, enhancing its market position and reducing sales costs [8][24] Challenges and Risks - The heparin raw material business faces challenges from price fluctuations due to the pig farming cycle and epidemic risks, but a price stabilization is expected by 2025 [28] - The company has taken measures to mitigate risks, including significant inventory write-downs, allowing for flexible price adjustments [28] Conclusion - Jianyou Co., Ltd. is well-positioned for future growth with a strong product pipeline, significant market opportunities in biosimilars, and a robust production capacity. The company is expected to benefit from favorable regulatory changes and market dynamics, making it an attractive investment opportunity [10][29]

导读： 近日，诺华核药Pluvicto新适应症上市申请获CDE受理，这是该药在中国申报的第二个适应症，2024 年， Pluvicto 销售额达 13.9亿美元，是首个年销售 额破10亿美元的核药。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 诺华核药Pluv i c t o新适应症上市申请获CDE受理 ，这是该药在中国申报的第二个适应症，此次新适应症若获批，将进一步扩大其覆盖 人群，把治疗线数前移至化疗前阶段。 | 序号 | 受理号 | 药品名称 | 药品类型 | 申请类型 | 注册分类 | 企业名称 | 承力日期 | | --- | --- | --- | --- | --- | --- | --- | --- | | | JXHS2500054 | 撸[177Lu] 特昔维匹肽 | 化药 | 进口 | | Novartis Pharma AG;Advanced Accelerator | 2025-04-28 | | | | | | | | Schweiz | | | | | 注射液 | | | 5.1 | | | | | ...

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [49]. Core Views - The chemical agents and blood products sectors are expected to perform outstandingly in 2024, with positive revenue and profit growth reported in the CXO and medical services (hospitals) sectors for Q1 2025 [4][5]. - The biopharmaceutical industry is anticipated to outperform the market overall [4]. Summary by Sections Industry Performance - As of April 30, 2025, 467 A-share biopharmaceutical companies reported their 2024 annual and Q1 2025 results. In 2024, 28 companies had revenue growth exceeding 30%, while 50 companies exceeded 20%, and 113 companies exceeded 10%. Approximately 220 companies reported positive revenue growth, while 246 experienced negative growth. On the profit side, 102 companies had profit growth over 30%, 132 over 20%, and 172 over 10%, with 218 maintaining positive profit growth and 249 facing negative growth [4]. - In Q1 2025, 24 companies reported revenue growth over 30%, 52 over 20%, and 109 over 10%, with 214 maintaining positive revenue growth and 251 reporting negative growth. For profits, 100 companies had growth over 30%, 120 over 20%, and 159 over 10%, with 220 maintaining positive profit growth and 240 facing negative growth [4]. Investment Strategies - Focus on "innovation," "going global," "equipment upgrades," and "consumption recovery." - **Innovation**: Invest in globally competitive innovative drugs and categories with significant market potential. Recommended companies include BeiGene, Dongcheng Pharmaceutical, and others [7]. - **Going Global**: Explore overseas markets for long-term opportunities, with companies like Mindray Medical and others highlighted [7]. - **Equipment Upgrades**: Expect support for medical equipment updates from central and local government financing, with companies like Mindray Medical and others recommended [7]. - **Consumption Recovery**: Anticipate recovery in quality sectors like ophthalmology and medical aesthetics, with companies such as Puri Eye Hospital and others suggested [7]. Key Companies to Watch - **Nocare Biopharma**: Expected to achieve over 1 billion yuan in revenue from its core product, with a 49% year-on-year sales increase. The company reported a gross margin of 86.3% and a significant reduction in losses [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with core products maintaining growth, and a robust pipeline expected to yield multiple approvals from 2025 to 2027 [11]. - **China Biopharmaceutical**: Rapid revenue growth with an increasing share of innovative products, and a strong pipeline in oncology [13]. - **Aibo Medical**: Anticipated growth in high-end artificial lenses and recovery in consumption due to aging trends [23]. Industry News Highlights - BeiGene's Sonrotoclax NDA application has been accepted for review, indicating potential market entry for a new treatment for CLL/SLL [30]. - Novartis' Pluvicto has received acceptance for a new indication in China, expanding its market potential [31]. - The partnership between Fuhong Hanlin and Sandoz for HLX13 indicates a significant milestone in the commercialization of biosimilars [33].

Group 1: Company Performance - Wens Foodstuff's April chicken sales revenue was 2.543 billion yuan, a year-on-year decrease of 5.01% [1] - Wens Foodstuff sold 10.381 million chickens in April, a year-on-year increase of 10.87% [1] - Wens Foodstuff's average chicken selling price was 11.24 yuan/kg, a year-on-year decrease of 14.91% [1] - Zhongtong Bus's April vehicle sales volume was 1,046 units, a year-on-year decrease of 4.04% [1][2] - Kemin Food's April pig sales revenue reached 70.9048 million yuan, a year-on-year increase of 16.04% [3] - Muyuan Foods sold 6.573 million pigs in April, a year-on-year increase of 51.80% [5] - Muyuan Foods' pig sales revenue was 12.595 billion yuan in April, a year-on-year increase of 53.42% [5] - Xiamen Airport's April passenger throughput was 2.3881 million, a year-on-year increase of 7.73% [24] - Daqin Railway's April cargo transport volume was 30.62 million tons, a year-on-year increase of 0.99% [26] - Shaanxi Coal's April coal production was 14.24 million tons, a year-on-year decrease of 1.78% [28] Group 2: Industry Overview - Wens Foodstuff operates in the agriculture, forestry, animal husbandry, and fishery industry, specifically in pig farming [1] - Zhongtong Bus operates in the automotive industry, focusing on commercial vehicles [2] - Kemin Food operates in the food and beverage industry, specifically in food processing [3] - Muyuan Foods is also in the agriculture, forestry, animal husbandry, and fishery industry, focusing on pig farming [5] - Xiamen Airport is part of the transportation industry, specifically in airport operations [24] - Daqin Railway operates in the coal industry, focusing on coal mining and transportation [26] - Shaanxi Coal is also in the coal industry, focusing on coal mining and related services [28]

证券代码：002675 证券简称：东诚药业 公告编号：2025-026 烟台东诚药业集团股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，烟台东诚药业集团股份有限公司（以下简称 "公司"）全资子公司 烟台东诚北方制药有限公司（以下简称"东诚北方"）收到国家药品监督管理局 核准签发的关于注射用氢化可的松琥珀酸钠的《药品补充申请批准通知书》，东 诚北方生产的注射用氢化可的松琥珀酸钠通过仿制药质量和疗效一致性评价（以 下简称"仿制药一致性评价"）。现将相关情况公告如下： | 药品名称 | 注射用氢化可的松琥珀酸钠 | | --- | --- | | 剂型 | 注射剂 | | 规格 | 50mg(按C₂₁H₃₀O₅计) 0.1g(按C₂₁H₃₀O₅计) | | 注册分类 | 化学药品 | | 受理号 | CYHB2450286 CYHB2450284 | | 通知书编号 | 2025B01909 2025B01907 | | 审批结论 | 根据《中华人民共和国药品管理法》、《国务院关于 | | | 改革药品医 ...

2、本次交易构成关联交易，不构成重大资产重组。 3、本次交易实施不存在重大法律障碍。 4、本次交易已经提交公司第六届董事会第十次会议审议通过，尚需提交股东大 会审议，关联董事由守谊先生回避了表决，其余4名非关联董事一致通过了该议案。 关于购买控股子公司少数股东股权暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次关联交易：烟台东诚药业集团股份有限公司以约3,600万元人民币收购 控股子公司烟台蓝纳成生物技术股份有限公司少数股东深圳景林景盈股权投资基金 合伙企业(有限合伙)所持1.65%股份。 证券代码：002675 证券简称：东诚药业 公告编号：2025-023 烟台东诚药业集团股份有限公司 一、交易概述 2023年6月21日，烟台东诚药业集团股份有限公司（以下简称 "东诚药业"或"公 司"）第五届董事会第十六次会议审议通过了《关于全资子公司增资扩股引进投资者 的议案》，同意控股子公司烟台蓝纳成生物技术股份有限公司（以下简称"蓝纳 成"）以增资扩股方式引入东诚药业、深圳景林景盈股权投资基金合伙企业(有限合 伙) （以下简称" ...

2025 年第一次临时股东大会通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 召开会议的基本情况 证券代码：002675 证券简称：东诚药业 公告编号：2025-024 烟台东诚药业集团股份有限公司 1、股东大会届次：本次股东大会为 2025 年第一次临时股东大会。 2、股东大会的召集人：公司董事会。2025 年 4 月 29 日公司第六届董事会 第十次会议审议通过召开公司 2025 年第一次临时股东大会的决议。 3、会议召开的合法、合规性：董事会作为本次股东大会召集人确认本次股 东大会会议召开符合有关法律、行政法规、部门规章、规范性文件、深圳证券交 易所业务规则和公司章程的规定。 4、会议召开日期、时间： 现场会议时间：2025 年 5 月 15 日下午 14:50。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 5 月 15 日 9:15－9:25，9:30-11:30，13:00－15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为：2025 年 5 月 15 日 9:15-15:00 期间的任 ...

证券代码：002675 证券简称：东诚药业 公告编号：2025-025 烟台东诚药业集团股份有限公司 第六届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 表决结果：同意3票，反对0票，弃权0票。 （二）审议通过了《关于购买控股子公司少数股东股权暨关联交易的议案》 经审核，监事会成员一致认为，本次交易价格是根据前期签订的协议内容及各 方协商所定，定价公允公平，不存在损害公司及全体股东利益的情形。回购资金全 部来源于公司的自有资金，公司财务状况良好，本次回购不会导致公司的合并报表 范围发生变化，不会对公司的持续经营和未来发展产生重大影响，亦不会对公司的 1 盈利能力、债务履行能力产生不利影响。 2025年4月29日，烟台东诚药业集团股份有限公司（以下简称"公司"）第六届 监事会第八次会议在本公司会议室召开。会议通知于2025年4月25日以通讯方式发送 至全体监事。本次会议由监事会主席柳青林先生主持，应出席监事3人，实出席监事 3人，董事会秘书刘晓杰先生列席，符合法律法规及公司章程的有关规定。 二、监事会会议审议情 ...